Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS -1.36%12 3-Year EPS without NRI Growth Rate is 16.90% as of Apr. 2026. GuruFocus rates KMTS with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 660 Medical Devices & Instruments companies, Kestra Medical Technologies ranks better than 60.45% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 16.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -18.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Kestra Medical Technologies was 16.90% per year. The lowest was -47.30% per year. And the median was -44.10% per year.
Kestra Medical Technologies (NAS:KMTS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Kestra Medical Technologies 3-Year EPS without NRI Growth Rate Related Terms
KMTS vs AZTA, STAA, BLFS: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's 3-Year EPS without NRI Growth Rate falls into.
Kestra Medical Technologies 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 16.90% mean?
Kestra Medical Technologies (KMTS) has a 3-Year EPS without NRI Growth Rate of 16.90% as of Apr. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Kestra Medical Technologies and its competitors. According to the industry distribution chart, Kestra Medical Technologies ranks #261 out of 660 companies in the Medical Devices & Instruments industry, placing it in the top 39.5%.
Is Kestra Medical Technologies' 3-Year EPS without NRI Growth Rate too high?
Kestra Medical Technologies' current 3-Year EPS without NRI Growth Rate is 16.90%. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.25. Kestra Medical Technologies' value of 16.90% is 104.8% above this industry median. Based on the distribution chart, Kestra Medical Technologies ranks #261 out of 660 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Kestra Medical Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' 3-Year EPS without NRI Growth Rate compare to AZTA and STAA?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #261 out of 660 companies for 3-Year EPS without NRI Growth Rate. This puts Kestra Medical Technologies in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.25. Kestra Medical Technologies' value of 16.90% is 104.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.25, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kestra Medical Technologies's current 3-Year EPS without NRI Growth Rate of 16.90% is 104.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Kestra Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current 3-Year EPS without NRI Growth Rate is 16.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current 3-Year EPS without NRI Growth Rate of 16.90%. The current 3-Year EPS without NRI Growth Rate is 16.90% and 104.8% above the Medical Devices & Instruments industry median of 8.25. Kestra Medical Technologies' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current 3-Year EPS without NRI Growth Rate is 16.90% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
12GF Score
Get the complete analysis for KMTS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
